RituximabAllergic reaction and leucopenia following off label use: 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1812卷 / 1期

关键词：

D O I：

10.1007/s40278-020-80730-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：251 / 251

相关论文

共 50 条

[41] Camrelizumab/rivoceranibHypertension, leucopenia and thrombocytopenia following off-label use: case report
Reactions Weekly, 2022, 1895 (1) : 111 - 111
[42] ExenatideNausea following off label use: 23 case reports
Reactions Weekly, 2017, 1657 (1) : 193 - 193
[43] RituximabNeuropathy following an off label use: 2 case reports
Reactions Weekly, 2020, 1820 (1) : 278 - 278
[44] LenvatinibFatal haemoptysis and pneumothorax following off-label use: 3 case reports
Reactions Weekly, 2021, 1844 (1) : 253 - 253
[45] Dexamethasone/prednisoneBacillary layer detachment following off label use: 3 case reports
Reactions Weekly, 2025, 2050 (1) : 192 - 192
[46] Multiple drugsLack of efficacy following off-label use: 3 case reports
Reactions Weekly, 2022, 1897 (1) : 251 - 251
[47] KetamineVarious toxicities following off-label use of ketamine: 3 case reports
Reactions Weekly, 2021, 1857 (1) : 187 - 187
[48] Amikacin/azithromycin/omadacyclineMultiple toxicities following off label use: 3 case reports
Reactions Weekly, 2022, 1924 (1) : 38 - 38
[49] PerampanelParadoxical atypical absence seizures following off label use: 3 case reports
Reactions Weekly, 2020, 1803 (1) : 201 - 201
[50] PembrolizumabHypophysitis, pancreatitis and pneumonia following off-label use: 3 case reports
Reactions Weekly, 2022, 1934 (1) : 360 - 360

← 1 2 3 4 5 →